ProfileGDS5678 / 1434880_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 85% 80% 88% 84% 83% 86% 87% 85% 84% 85% 85% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3659485
GSM967853U87-EV human glioblastoma xenograft - Control 26.4463285
GSM967854U87-EV human glioblastoma xenograft - Control 35.702380
GSM967855U87-EV human glioblastoma xenograft - Control 47.0550688
GSM967856U87-EV human glioblastoma xenograft - Control 56.3329784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8197183
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3502786
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5857987
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3174685
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3249184
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.317385
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4508685
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3290885
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2605185